By Brad Sorensen, CFA
NASDAQ: COSM
READ THE FULL COSM RESEARCH REPORT
Cosmos Health (NASDAQ: COSM) delivered a strong second-quarter update that, in our view, provides additional evidence that the company is transitioning from a collection of healthcare assets into a larger, vertically integrated healthcare platform with increasingly meaningful scale. The headline numbers were encouraging: record second-quarter and first-half revenue, significant growth in adjusted gross profit, improving adjusted EBITDA, better operating leverage, a stronger balance sheet, and continued share repurchases. Perhaps more important for longer-term investors, several of Cosmos Health's growth initiatives—including CosmoFarm, Cana Laboratories, proprietary nutraceuticals, international distribution and the company's developing U.S. business—are beginning to contribute simultaneously.
Cosmos Health is a diversified healthcare company with operations spanning pharmaceutical distribution, manufacturing, proprietary nutraceutical and pharmaceutical brands, healthcare products, and research and development. Its vertically integrated structure differentiates it from a traditional pharmaceutical distributor. The company owns brands including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through Cana Laboratories, Cosmos operates an EU-GMP pharmaceutical manufacturing business capable of producing pharmaceuticals, supplements, cosmetics, biocides and medical devices. Meanwhile, CosmoFarm provides pharmaceutical distribution in Greece, and Decahedron serves the UK market.
Record Q2 Results Demonstrate Accelerating Scale
We believe the most important takeaway from the Q2 release is the strength of revenue growth. Second-quarter revenue reached a record $18.99 million, up 28.8% from $14.75 million a year ago. First-half revenue increased 29.7% to $36.91 million from $28.46 million. Adjusting for certain sales discount reversals, Q2 revenue was $19.32 million, up 31%, while first-half adjusted revenue reached $37.72 million, up 32.5%. Management noted that this represents an adjusted annualized revenue run rate exceeding $75 million.
We see this as an important milestone because Cosmos generated only $65.3 million of revenue during all of 2025. The current run rate suggests to us that the company's growth trajectory has moved meaningfully higher even before incorporating potential acquisitions and the historically stronger seasonality management expects during the second half.
The quality of the Q2 growth also appears to be improving. Reported gross profit increased 29.9% to $1.51 million, roughly matching revenue growth. More impressively, adjusted gross profit increased 58.4% to $1.84 million, while adjusted gross margin expanded 165 basis points to 9.54%.
This margin expansion is particularly significant to the COSM investment case. Cosmos has historically generated a substantial portion of revenue from relatively low-margin pharmaceutical distribution. As higher-margin proprietary products, contract manufacturing, and specialized healthcare products become larger contributors, there is an opportunity for gross profit to grow materially faster than revenue. Q2 provides some early evidence of that progression.
Operating Leverage Is Beginning to Emerge
Another very encouraging feature of the quarter to us was the expense control relative to growth. Operating expenses increased 16.5% to $4.44 million while revenue grew 28.8%. Salaries and wages actually declined 0.7% year over year despite the substantial increase in revenue. Management also reported that receivables and inventory declined even as sales approached 30% growth; first-half inventory was down 21.8%.
These figures suggest that Cosmos is beginning to generate operating leverage. Revenue is growing considerably faster than the expense base, while inventory management and collections are becoming more efficient. This dynamic could become increasingly important as revenue scales because a greater portion of incremental gross profit could ultimately flow through to EBITDA.
Adjusted EBITDA provides another encouraging indicator. The Q2 adjusted EBITDA loss improved to $1.13 million from a loss of $1.31 million a year earlier despite continued investment in international expansion and proprietary brands.
The reported net loss of $6.09 million appears much less favorable, compared with a $2.83 million loss a year ago. However, approximately $2.65 million of the quarterly loss reflected non-cash charges, principally fair-value adjustments associated with financing arrangements and not as a result of core operations.
CosmoFarm Is Becoming a Significant Revenue Engine
Within the COSM universe, CosmoFarm continues to be one of the largest drivers of growth. The business generated more than $15 million of quarterly revenue during Q2, equivalent to an annualized run rate exceeding $60 million, while adding more than 75 pharmacies to its distribution network.
Cosmos is also investing in robotic automation and AI technology at CosmoFarm. Combined with the company's broader AI initiatives in inventory, warehousing, procurement, and order management, management believes technology could reduce certain operating expenses by as much as 30%.
We believe CosmoFarm provides a large and expanding revenue base and pharmacy distribution infrastructure, while automation potentially creates an avenue for better margins as volume increases.
Cana Laboratories Provides Growing Visibility
While CosmoFarm growth is impressive, Cana Laboratories may ultimately prove even more important from a profitability standpoint. Its contract manufacturing orderbook has reached an all-time high exceeding 25 million units across nine therapeutic categories, with agreements extending for periods of up to ten years.
Recent agreements include a 3.9-million-unit contract with Verisfield for VASCLOR GEST progesterone pessaries and a 2.86-million-unit agreement with Pharmex covering three dermatological products. Additional orders from Nassington and Verisfield totaled more than 253,000 units, while Cosmos inaugurated a new capsule manufacturing line accompanied by a five-year agreement with Provident Pharmaceuticals for 385,000 units of CERTORUN.
This expanding orderbook is attractive because it provides Cosmos with greater revenue visibility than ordinary pharmaceutical distribution. Long-duration manufacturing agreements can also improve utilization of Cana's production infrastructure, potentially increasing margins as manufacturing volumes rise.
Additionally, Cana entered an advisory agreement with the European Investment Bank regarding potential financing of Cosmos' R&D program. The company indicated that EIB financing could total as much as €25 million. We don’t believe this should be viewed as committed financing at this stage, but successful completion could provide a significant source of capital for R&D without relying entirely on conventional equity funding.
Proprietary Products Could Change the Margin Profile
Cosmos continues to expand its higher-margin proprietary brands internationally. Sky Premium Life achieved pan-European distribution through Skroutz, making its products available across all 27 EU member states. The company also signed a distribution agreement with International Medical Company in Qatar, including an initial order for 31,000 Sky Premium Life units, and received another 60,000-unit order from Pharmalink in the UAE, bringing cumulative orders from that relationship to 270,000 units.
C-Scrub and C-Sept are also becoming increasingly meaningful. Combined annualized sales have exceeded $1.5 million in Greece and the UK. Cosmos believes planned European expansion could ultimately generate approximately $7.4 million in revenue and $5.3 million in gross profit—an implied margin dramatically above the company's consolidated margin today.
Another recent product, C-Scrub Wash 4%, successfully completed EN 12791 testing, the European standard covering surgical hand disinfection. That potentially opens hospital, surgical, and professional healthcare markets. Separately, successful EN 1656 and EN 1657 testing has allowed Cosmos to target the approximately $69 billion global animal-health market with a veterinary formulation of C-Scrub Wash 4%.
These developments demonstrate to us why proprietary products matter so much to the long-term COSM story. Distribution establishes scale, but proprietary products potentially provide the margins capable of transforming the company's earnings profile.
The U.S. Opportunity Adds Another Growth Driver
We see the company's U.S. expansion as another potentially important catalyst. During Q2, Cosmos moved its "18 Series" from concept toward commercialization. The platform is intended to eventually contain 18 clinically validated nutraceutical products addressing areas including liver health, joint and inflammation support, cardiovascular health, men's wellness and healthy aging. Cosmos also entered the global skincare market, which the company estimates at approximately $163 billion, with U.S. sales already underway.
The attraction of the U.S. strategy is not simply additional revenue. Proprietary nutraceutical and skincare products have the potential to generate substantially higher margins than pharmaceutical wholesaling. Management has described the United States as a prospective principal growth engine, supported by local manufacturing.
Balance Sheet Improvement Is an Underappreciated Positive
The Q2 release also contained meaningful balance-sheet progress. Total liabilities declined $6.27 million, or 13.3%, from year-end to $40.79 million. At the same time, stockholders' equity increased $2.25 million, or 12.2%, to $20.67 million. The liabilities-to-assets ratio improved by 550 basis points, from 71.9% to 66.4%. Cosmos reported $4.15 million of liquid assets consisting of cash, marketable securities, and digital assets.
Management has additionally identified approximately $20 million of non-core assets that potentially could be monetized to fund growth or improve the capital structure. The company also signed an LOI to acquire Doc Pharma S.A., an affiliated European GMP pharmaceutical manufacturer.
Management's actions regarding the stock are also encouraging to us. Cosmos authorized a share repurchase program of up to $5 million in June. It repurchased 2.65 million shares for approximately $513,000 during Q2, and purchases continued during Q3. As of today's announcement, Cosmos had repurchased approximately 5.112 million shares for roughly $1.11 million.
At the same time, approximately 4.87 million Series B warrants expired unexercised during the quarter, eliminating roughly 38% of the company's warrant overhang without additional dilution.
For shareholders, the combination of reduced warrant overhang and active open-market repurchases should be encouraging to further increase the value of remaining shares.
Longer-Term Outlook
The most compelling element of the COSM story to us is the changing composition of the business. Cosmos increasingly combines the scale of pharmaceutical distribution, the recurring potential of contract manufacturing, the higher margins of proprietary healthcare products, international expansion, U.S. nutraceutical opportunities and an emerging R&D portfolio.
Q2 2026 provides evidence that this strategy is gaining traction. Revenue increased nearly 29%, adjusted gross profit increased 58%, adjusted gross margin expanded 165 basis points, operating expenses grew considerably more slowly than revenue, adjusted EBITDA improved, liabilities declined 13%, equity increased 12%, and management continued buying back shares. At the operating level, CosmoFarm surpassed a $60 million annualized revenue pace, Cana's manufacturing orderbook exceeded 25 million units, international orders for Sky Premium Life continued to expand, and C-Scrub and C-Sept moved into potentially valuable new markets.
COSM remains a higher-risk small-cap investment, and those risks should not be minimized. However, today's Q2 report strengthens our positive investment view: Cosmos is considerably larger than it was a year ago, its adjusted profitability metrics are improving, its balance sheet is moving in the right direction, and several potentially high-margin businesses remain at relatively early stages of commercialization.
For investors willing to accept the risks associated with a small-cap healthcare company, the combination of nearly 30% first-half revenue growth, improving operating leverage, a growing manufacturing backlog, international expansion, a developing U.S. platform, proprietary products, and management's willingness to repurchase shares creates a potentially attractive setup.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.